# Companio Project Status

**Owner category:** Engineering and Governance  
**Status:** Current summary based on repository records inspected on 2026-11-12  
**Last verified:** 2026-11-12

## Repository baseline

- Repository: [Pranjal-k22/Companio](https://github.com/Pranjal-k22/Companio)
- Default branch: main
- Visibility: Public
- This audit inspected the default-branch tree and selected source/documentation files; it does not assert a local working-tree state.

## Engineering milestone status

The repository contains completion reports recording capabilities through Phase 12.2. Phase reports are historical records; their test results should be rerun in the target environment before release decisions.

| Milestone | Repository evidence | Recorded status |
|---|---|---|
| Phases 1–8 | Individual completion reports | Reported complete |
| Phase 9 | Queue architecture and completion report | Reported complete |
| Phase 9.1 | Redis validation report | Reported complete against a local standalone Redis 8.10.3 instance |
| Phase 10 | Operations and release-gate documents | Reported complete |
| Phase 11 | Security, privacy, clinical hazard and provider assessments | Assessment reported complete; external prerequisites remain |
| Phase 12 | Synthetic end-to-end and password recovery documents | Reported complete |
| Phase 12.1 | External readiness governance and four-tier release gates | Documentation complete; external approvals pending |
| Phase 12.2 | Pilot-safe alert minimization and closure tracking | Reported complete; external blockers remain |
| Phase 12.2.1 | Described in supplied execution context, but expected report files were not found at expected repository paths | Not verified in repository |

## Current release restrictions

| Activity | Recorded status | Evidence required to change status |
|---|---|---|
| Synthetic-data development and CI | GO / allowed | Continue test hygiene and secret controls |
| Human usability recruitment | BLOCKED pending written IRB determination | Verify written IRB approval and approved protocol |
| Controlled clinical cohort pilot | BLOCKED | Clinical governance sign-off, approved protocol, safe data flow and provider/legal approval |
| Commercial production with real patient data | NO-GO / BLOCKED | Provider contracts and privacy/legal approval, independent penetration test, clinical governance and operational sign-off |

See [production readiness matrix](PHASE_12_PRODUCTION_READINESS_MATRIX.md), [provider closure register](PHASE_12_2_PROVIDER_CLOSURE.md), [clinical sign-off tracker](PHASE_12_2_CLINICAL_SIGNOFF_TRACKER.md), [IRB tracker](PHASE_12_2_IRB_APPROVAL_TRACKER.md) and [penetration test tracker](PHASE_12_2_PENETRATION_TEST_TRACKER.md).

## Privacy terminology

The repository contains heuristic data-minimization and pseudonymization for outbound alerts. This is not proof of HIPAA Safe Harbor or Expert Determination. Do not send real patient PHI to external providers whose agreements and configurations have not been reviewed and approved for that use.

## Known documentation inconsistencies

1. Early TRD material refers to older providers (Deepgram/OpenAI/Nodemailer). Use current package manifests and implementation modules for current dependencies.
2. The UI/UX information architecture has caregiver portal areas marked planned, while later Phase 8 docs and current frontend source include caregiver modules. Reconcile exact routes before relying on the older sitemap.
3. Phase 12.2.1 report files described in supplied execution context were not present at expected paths during this repository inventory.
4. Existing specialized and phase-specific documentation remains at the root of docs; this consolidation indexes rather than moves historical files.

## Next evidence-driven work

1. Close provider agreement and data-processing review.
2. Obtain independent external security testing and retest results.
3. Obtain clinical review/sign-off for safety taxonomy and emergency guidance.
4. Obtain written IRB determination before human recruitment.
5. Conduct approved human-factors sessions and preserve actual results.
6. Reassess Tier A–D decisions using evidence, not documentation completeness alone.